Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Retained Earnings (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Retained Earnings data on record, last reported at -$1.2 million in Q3 2025.

  • For Q3 2025, Retained Earnings rose 99.91% year-over-year to -$1.2 million; the TTM value through Sep 2025 reached -$1.2 million, up 99.91%, while the annual FY2024 figure was -$1.4 billion, 6.16% down from the prior year.
  • Retained Earnings reached -$1.2 million in Q3 2025 per NWBO's latest filing, up from -$1.5 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $2.2 million in Q2 2024 and bottomed at -$1.5 billion in Q2 2025.
  • Average Retained Earnings over 5 years is -$641.0 million, with a median of -$4.9 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: soared 131.1% in 2021, then plummeted 3339110.53% in 2022.
  • A 5-year view of Retained Earnings shows it stood at $357000.0 in 2021, then tumbled by 363439.5% to -$1.3 billion in 2022, then dropped by 4.83% to -$1.4 billion in 2023, then decreased by 6.16% to -$1.4 billion in 2024, then skyrocketed by 99.92% to -$1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$1.2 million in Q3 2025, -$1.5 billion in Q2 2025, and $1.4 million in Q1 2025.